modelPerindopril

Diagram of Perindopril

Extends from Pharmacolibrary.Drugs.ATC.C.C09AA04.

Information

name:Perindopril
ATC code:C09AA04
route:oral
compartments:1
dosage:4mg
volume of distribution:0.7L
clearance:327mL/min
other parameters in model implementation

Perindopril is an angiotensin-converting enzyme (ACE) inhibitor used primarily for the treatment of hypertension, heart failure, and stable coronary artery disease. It is an approved medication and is prescribed widely across the world to help lower blood pressure and protect heart function.

Pharmacokinetics

Pharmacokinetic parameters for perindopril reported in healthy adult subjects after single oral dosing.

References

  1. Anderson, PJ, et al., & Resplandy, G (1995). Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers. British journal of clinical pharmacology 39(4) 361–368. DOI:10.1111/j.1365-2125.1995.tb04463.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/7640141

  2. Ding, PY, et al., & Liao, W (2000). Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors?. Journal of human hypertension 14(3) 163–170. DOI:10.1038/sj.jhh.1000856 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10694829

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)